免疫检查点抑制剂导致免疫相关性肺炎的诊治进展
摘要
<正>免疫治疗是继手术、放疗、化疗后第四类恶性肿瘤治疗手段,其中免疫检查点抑制剂(check-point inhibitor,CPIs)是近年来肿瘤治疗领域取得的重大进展,为晚期黑色素瘤、肾癌、非小细胞肺癌等多种恶性肿瘤的患者带来了福音[1]。目前肿瘤免疫治疗仅在美国就有至少50种CPIs正在药物研发中,有800多项有关肿瘤免疫治疗的临床研
引文
[1]Alsaab HO,Sau S,Alzhrani R,et al.PD-1 and PD-L1checkpoint signaling inhibition for cancer immunotherapy:mechanism,cmbinations,and clinical outcome[J].Front Pharmacol,2017,8:561.
[2]Oncology TL.Calling time on the immunotherapy gold rush[J].Lancet Oncology,2017,18(8):981.
[3]Suresh K,Psoter KJ,Voong KR,et al.Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy[J].J Thorac Oncol,2019,14(3):494-502.
[4]Akella P,Loganathan S,Jindal V,et al.Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure-A review with case series[J].Respir Med Case Rep,2019,26:17-22.
[5]Bianco A,Malapelle U,Rocco D,et al.Targeting immune checkpoints in non small cell lung cancer[J].Curr Opin Pharmacol,2018,40:46-50.
[6]Calabrese LH,Calabrese C,Cappelli LC.Rheumatic immunerelated adverse events from cancer immunotherapy[J].Nat Rev Rheumatol,2018,14(10):569-579.
[7]Buchbinder EI,Desai A.CTLA-4 and PD-1 Pathways:Similarities,differences,and implications of their inhibition[J].Am J Clin Oncol,2016,39(1):98-106.
[8]Champiat S,Lambotte O,Barreau E,et al.Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper[J].Ann Oncol,2016,27(4):559-574.
[9]Nishino M,Giobbie-Hurder A,Hatabu H,et al.Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer:A systematic review and meta-analysis[J].Jama Oncol,2016,2(12):1607.
[10]Kato T,Masuda N,Nakanishi Y,et al.Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer[J].Lung Cancer,2017,104:111-118.
[11]Naidoo J,Wang X,Woo KM,et al.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J].J Clin Oncol,2017,35(7):709-717.
[12]Balaji A,Verde F,Suresh K,et al.Pneumonitis from antiPD-1/PD-L1 therapy[J].Oncology(Williston Park),2017,31(10):739-746,754.
[13]Hassel JC,Heinzerling L,Aberle J,et al.Combined immune checkpoint blockade(anti-PD-1/anti-CTLA-4):Evaluation and management of adverse drug reactions[J].Cancer Treatment Reviews,2017,57:36-49.
[14]Friedman CF,Proverbs-Singh TA,Postow MA.Treatment of the immune-related adverse effects of immune checkpoint inhibitors:A review[J].JAMA Oncol,2016,2(10):1346-1353.
[15]Nishino M,Ramaiya NH,Awad MM,et al.PD-1 inhibitorrelated pneumonitis in advanced cancer patients:Radiographic patterns and clinical course[J].Clin Cancer Res,2016,22(24):6051-6060.
[16]Delaunay M,Cadranel J,Lusque A,et al.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients[J].Eur Respir J,2017,50(2):pii1700050.
[17]Abdel-Rahman O,Fouad M.Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors:a meta-analysis[J].Ther Adv Respir Dis,2016,10(3):183-193.
[18]Li H,Ma W,Yoneda KY,et al.Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory,metastatic lung squamous cell cancer:a case report[J].Journal of Hematology&Oncology,2017,10(1):64.
[19]Koelzer VH,Rothschild SI,Zihler D,et al.Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study[J].J Immunother Cancer,2016,4:13.
[20]Fishman JA,Hogan JI,Maus MV.Inflammatory and infectious syndromes associated with cancer immunotherapies[J].Clin Infect Dis,2018 Dec 6.[Epub ahead of print]
[21]Chuzi S,Tavora F,Cruz M,et al.Clinical features,diagnostic challenges,and management strategies in checkpoint inhibitor-related pneumonitis[J].Cancer Manag Res,2017,9:207-213.
[22]Brahmer JR,Lacchetti C,Schneider BJ,et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American society of clinical oncology clinical practice guideline[J].J Clin Oncol,2018,36(17):1714-1768.
[23]Haanen J,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv264-iv266.
[24]Gettinger SN,Horn L,Gandhi L,et al.Overall survival and long-term safety of nivolumab(Anti-Programmed Death 1Antibody,BMS-936558,ONO-4538)in patients with previously treated advanced non-small-cell lung cancer[J].JClin Oncol,2015,33(18):2004-2012.
[25]Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.
[2]Oncology TL.Calling time on the immunotherapy gold rush[J].Lancet Oncology,2017,18(8):981.
[3]Suresh K,Psoter KJ,Voong KR,et al.Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy[J].J Thorac Oncol,2019,14(3):494-502.
[4]Akella P,Loganathan S,Jindal V,et al.Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure-A review with case series[J].Respir Med Case Rep,2019,26:17-22.
[5]Bianco A,Malapelle U,Rocco D,et al.Targeting immune checkpoints in non small cell lung cancer[J].Curr Opin Pharmacol,2018,40:46-50.
[6]Calabrese LH,Calabrese C,Cappelli LC.Rheumatic immunerelated adverse events from cancer immunotherapy[J].Nat Rev Rheumatol,2018,14(10):569-579.
[7]Buchbinder EI,Desai A.CTLA-4 and PD-1 Pathways:Similarities,differences,and implications of their inhibition[J].Am J Clin Oncol,2016,39(1):98-106.
[8]Champiat S,Lambotte O,Barreau E,et al.Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper[J].Ann Oncol,2016,27(4):559-574.
[9]Nishino M,Giobbie-Hurder A,Hatabu H,et al.Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer:A systematic review and meta-analysis[J].Jama Oncol,2016,2(12):1607.
[10]Kato T,Masuda N,Nakanishi Y,et al.Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer[J].Lung Cancer,2017,104:111-118.
[11]Naidoo J,Wang X,Woo KM,et al.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J].J Clin Oncol,2017,35(7):709-717.
[12]Balaji A,Verde F,Suresh K,et al.Pneumonitis from antiPD-1/PD-L1 therapy[J].Oncology(Williston Park),2017,31(10):739-746,754.
[13]Hassel JC,Heinzerling L,Aberle J,et al.Combined immune checkpoint blockade(anti-PD-1/anti-CTLA-4):Evaluation and management of adverse drug reactions[J].Cancer Treatment Reviews,2017,57:36-49.
[14]Friedman CF,Proverbs-Singh TA,Postow MA.Treatment of the immune-related adverse effects of immune checkpoint inhibitors:A review[J].JAMA Oncol,2016,2(10):1346-1353.
[15]Nishino M,Ramaiya NH,Awad MM,et al.PD-1 inhibitorrelated pneumonitis in advanced cancer patients:Radiographic patterns and clinical course[J].Clin Cancer Res,2016,22(24):6051-6060.
[16]Delaunay M,Cadranel J,Lusque A,et al.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients[J].Eur Respir J,2017,50(2):pii1700050.
[17]Abdel-Rahman O,Fouad M.Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors:a meta-analysis[J].Ther Adv Respir Dis,2016,10(3):183-193.
[18]Li H,Ma W,Yoneda KY,et al.Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory,metastatic lung squamous cell cancer:a case report[J].Journal of Hematology&Oncology,2017,10(1):64.
[19]Koelzer VH,Rothschild SI,Zihler D,et al.Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study[J].J Immunother Cancer,2016,4:13.
[20]Fishman JA,Hogan JI,Maus MV.Inflammatory and infectious syndromes associated with cancer immunotherapies[J].Clin Infect Dis,2018 Dec 6.[Epub ahead of print]
[21]Chuzi S,Tavora F,Cruz M,et al.Clinical features,diagnostic challenges,and management strategies in checkpoint inhibitor-related pneumonitis[J].Cancer Manag Res,2017,9:207-213.
[22]Brahmer JR,Lacchetti C,Schneider BJ,et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American society of clinical oncology clinical practice guideline[J].J Clin Oncol,2018,36(17):1714-1768.
[23]Haanen J,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv264-iv266.
[24]Gettinger SN,Horn L,Gandhi L,et al.Overall survival and long-term safety of nivolumab(Anti-Programmed Death 1Antibody,BMS-936558,ONO-4538)in patients with previously treated advanced non-small-cell lung cancer[J].JClin Oncol,2015,33(18):2004-2012.
[25]Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.